poster

EMPOWERing the Next-Generation: A phase 2 Program to Evaluate Emraclidine, a Selective M4 Positive Allosteric Modulator (PAM), for the Treatment of Schizophrenia

Detailed study designs for the EMPOWER program will be presented. Primary outcome measure for EMPOWER 1 and 2 is change from baseline in PANSS total score at week 6. Other outcome measure...

10/26/2023

Enhancing Access to Mental Health Services: The Growing Use of Telemedicine Among Physician Assistants/Associates in Psychiatry

Challenges to accessing affordable and high-quality mental health care persist amidst significantly rising demand. This study explored the use of telemedicine technology among PAs practic...

10/26/2023

Equivalent Antidepressant Outcomes with Esketamine in TMS Non-Responders

Both Transcranial Magnetic Stimulation (TMS) and Esketamine are FDA approved therapies for patients with Major Depressive Disorder who have failed at least one conventional antidepressant...

10/26/2023

Esketamine Nasal Spray Improves Functioning in Patients with Treatment Resistant Depression: Results from ESCAPE‑TRD

This analysis evaluated changes in functioning and productivity in patients with treatment resistant depression who received either esketamine nasal spray or quetiapine extended release, ...

10/26/2023

Effects of Solriamfetol on Cognition in Participants with Cognitive Impairment Associated with Excessive Daytime Sleepiness in Obstructive Sleep Apnea: SHARP Study Results

The SHARP trial evaluated solriamfetol's effect on cognitive function in patients with obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS)-related cognitive impairment. T...

10/26/2023

Efficacy and Engagement With a Digital Therapeutic in Patients With Experiential Negative Symptoms of Schizophrenia

Currently, there are no effective pharmacotherapies approved for experiential negative symptoms (ENS) of schizophrenia. Digital therapeutics (DTx) may represent a feasible option given ub...

10/26/2023

Efficacy and Safety of Iclepertin (BI 425809) in Patients with Schizophrenia: CONNEX, a Phase III Randomized Controlled Trial Program

Cognitive impairment is a major determinant of poor functional outcomes in schizophrenia. Currently, studies testing potential treatments for cognitive impairment have failed to demonstra...

10/26/2023

Efficacy and Safety of Paliperidone Palmitate 6-Month Formulation: A 3-Year Analysis in Adults With Schizophrenia

This analysis assessed the efficacy and safety of paliperidone palmitate 6-month (PP6M) in adults with schizophrenia who remained relapse free after a 1-year double-blind study (NCT033453...

10/26/2023

Efficacy and Safety of Seltorexant in Insomnia Disorder

In a double-blind, randomized, parallel-group, active- and placebo-controlled, 14-day, dose-finding study in adult/elderly subjects with insomnia disorder, the 10 mg and 20 mg dose groups...

10/26/2023

Efficacy and Safety Outcomes When Transitioning to Paliperidone Palmitate 6-Month From Paliperidone Palmitate 1-Month Versus Paliperidone Palmitate 3-Month

This post hoc analysis of a non-inferiority study (NCT03345342) found that adult patients with schizophrenia who transition to palmitate 6-month (PP6M) from either paliperidone palmitate ...

10/26/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products